
Milan-based biotech firm Dompé has revealed that the FDA has awarded approval in the US to its Oxervate (cenegermin-bkbj ophthalmic …

NICE has announced that it has recommended against the use of Dompe’s recombinant human nerve growth factor eye drop therapy …

